| John Obert, | |
|
1717 6th Ave S, Birmingham, AL 35233-1801 | |
| (800) 822-8816 | |
| Not Available |
| Full Name | John Obert |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 8 Years |
| Location | 1717 6th Ave S, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316392103 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 36514 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Alabama Hospital | Birmingham, AL | Hospital |
| Citizens Baptist Medical Center | Talladega, AL | Hospital |
| Princeton Baptist Medical Center | Birmingham, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alteon Health Alabama, Llc | 5698830552 | 31 |
News Archive
The urine of kidney disease patients contains a diverse mix of bacteria such as Staphylococcus and Streptococcus, according to a study by researchers at Loyola Medicine and Loyola University Chicago.
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A newly published report reveals that children with epilepsy are more likely to have psychiatric symptoms, with gender a determining factor in their development.
› Verified 5 days ago
| Entity Name | University Of Alabama Health Services Foundation, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
The urine of kidney disease patients contains a diverse mix of bacteria such as Staphylococcus and Streptococcus, according to a study by researchers at Loyola Medicine and Loyola University Chicago.
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A newly published report reveals that children with epilepsy are more likely to have psychiatric symptoms, with gender a determining factor in their development.
› Verified 5 days ago
| Entity Name | Paragon Contracting Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225071459 PECOS PAC ID: 3971417825 Enrollment ID: O20050218000756 |
News Archive
The urine of kidney disease patients contains a diverse mix of bacteria such as Staphylococcus and Streptococcus, according to a study by researchers at Loyola Medicine and Loyola University Chicago.
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A newly published report reveals that children with epilepsy are more likely to have psychiatric symptoms, with gender a determining factor in their development.
› Verified 5 days ago
| Entity Name | Alteon Health Alabama, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477708857 PECOS PAC ID: 5698830552 Enrollment ID: O20090210000557 |
News Archive
The urine of kidney disease patients contains a diverse mix of bacteria such as Staphylococcus and Streptococcus, according to a study by researchers at Loyola Medicine and Loyola University Chicago.
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A newly published report reveals that children with epilepsy are more likely to have psychiatric symptoms, with gender a determining factor in their development.
› Verified 5 days ago
| Entity Name | App Of Alabama Ed Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659646040 PECOS PAC ID: 3577725068 Enrollment ID: O20120430000174 |
News Archive
The urine of kidney disease patients contains a diverse mix of bacteria such as Staphylococcus and Streptococcus, according to a study by researchers at Loyola Medicine and Loyola University Chicago.
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A newly published report reveals that children with epilepsy are more likely to have psychiatric symptoms, with gender a determining factor in their development.
› Verified 5 days ago
| Entity Name | Emergency Services Of Montgomery Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528310323 PECOS PAC ID: 6608028204 Enrollment ID: O20121205000519 |
News Archive
The urine of kidney disease patients contains a diverse mix of bacteria such as Staphylococcus and Streptococcus, according to a study by researchers at Loyola Medicine and Loyola University Chicago.
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A newly published report reveals that children with epilepsy are more likely to have psychiatric symptoms, with gender a determining factor in their development.
› Verified 5 days ago
| Entity Name | Alabama Emergency Physician Partners, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891031894 PECOS PAC ID: 4082868641 Enrollment ID: O20130206000466 |
News Archive
The urine of kidney disease patients contains a diverse mix of bacteria such as Staphylococcus and Streptococcus, according to a study by researchers at Loyola Medicine and Loyola University Chicago.
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A newly published report reveals that children with epilepsy are more likely to have psychiatric symptoms, with gender a determining factor in their development.
› Verified 5 days ago
| Entity Name | Nes Tennessee, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437606605 PECOS PAC ID: 3678472040 Enrollment ID: O20161031002328 |
News Archive
The urine of kidney disease patients contains a diverse mix of bacteria such as Staphylococcus and Streptococcus, according to a study by researchers at Loyola Medicine and Loyola University Chicago.
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A newly published report reveals that children with epilepsy are more likely to have psychiatric symptoms, with gender a determining factor in their development.
› Verified 5 days ago
| Entity Name | Gadsden Hb Medical Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750061610 PECOS PAC ID: 4183078561 Enrollment ID: O20231004001282 |
News Archive
The urine of kidney disease patients contains a diverse mix of bacteria such as Staphylococcus and Streptococcus, according to a study by researchers at Loyola Medicine and Loyola University Chicago.
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A newly published report reveals that children with epilepsy are more likely to have psychiatric symptoms, with gender a determining factor in their development.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Obert, 1717 6th Ave S, Birmingham, AL 35233-1801 Ph: () - | John Obert, 1717 6th Ave S, Birmingham, AL 35233-1801 Ph: (800) 822-8816 |
News Archive
The urine of kidney disease patients contains a diverse mix of bacteria such as Staphylococcus and Streptococcus, according to a study by researchers at Loyola Medicine and Loyola University Chicago.
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A newly published report reveals that children with epilepsy are more likely to have psychiatric symptoms, with gender a determining factor in their development.
› Verified 5 days ago
Janyce M Sanford, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1806 Sixth Avenue South, Birmingham, AL 35249 Phone: 205-975-7389 Fax: 205-975-4662 | |
Dr. Elizabeth Holcombe Adams, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 218 Devon Dr, Birmingham, AL 35209 Phone: 662-368-8602 | |
Dr. Melissa Leigh Peters, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1600 7th Ave S, Birmingham, AL 35233 Phone: 205-638-9587 Fax: 205-975-4623 | |
Alan Frederick Kitchens, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 50 Medical Park Dr E, St. Vincent's East, Birmingham, AL 35235 Phone: 205-545-9530 Fax: 205-545-9529 | |
John Gullett, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-5038 | |
Dr. Edward Payson Daugherty, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 151 Narrows Pkwy, Suite 110, Birmingham, AL 35242 Phone: 205-444-9550 Fax: 205-314-3360 | |
Mary H Maddox, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1600 7th Ave S, Birmingham, AL 35233 Phone: 205-939-9587 Fax: 205-975-4623 |